ZNF217 and breast carcinoma: In conclusion, our data highlight that assessing the expression levels of ZNF217-WT and ZNF217-ΔE4 isoforms may serve as a novel prognostic biomarker allowing a better stratification of breast cancers with good prognosis and helping clinicians in therapeutic decisions.